Eli, Lilly and Company pharma partners on a five-year research partnership with the University of Surrey to study health outcomes, focusing on the effects of treatment in people with type 2 diabetes, which affects about 95 percent of those with the disease. Read the full story

Eli Lilly and Company, Anthem, Inc. and HealthCore pharma partners for a five-year, real-world evidence research collaboration intended to improve health outcomes for patients. Read the full story

QIAGEN announced a biotech partnership agreement with Astellas Pharma to develop and commercialize companion diagnostics paired with Astellas drugs for use in cancer and other diseases. Read the full story

Triphase Accelerator announced a new strategic pharma deal with Celgene. Read the full story

Molecular Devices has partnered with the Discovery Technologies team at the Roche announced a biotech partnership to develop a high-throughput detection system for drug discovery screens employing Roche's proprietary Ruthenium-based nanosecond time resolved fluorescence (Nano-TRF) assays. Read the full story

Bayer HealthCare and Kyoto University’s Office of Society-Academia Collaboration for Innovation pharma partners by signing a two-year agreement to jointly identify candidates for possible collaborative research projects. Read the full story

Forendo Pharma has entered into a definitive pharma licensing deal for the US development and commercialization rights for fispemifene to Apricus Biosciences. Read the full story

Cardiorentis announced a pharma partnership with Roche to establish the therapeutic efficacy and safety of Ularitide. Read the full story

Selecta Biosciences JDRF have extended their pharma partnership and attracted Sanofi as a partner in support of their program to develop a Synthetic Vaccine Particle immunotherapy with the long-term goal to treat and potentially prevent the underlying cause of type 1 diabetes. Read the full story

The University of Texas MD Anderson Cancer Center announced it formed a research alliance with GlaxoSmithKline to strengthen its efforts in advancing therapies that train the body's immune system to combat cancer. Read the full story